Results 91 to 100 of about 16,492 (195)

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9): The Multifaceted Biology, Diseases, and Pharmaceutical Interventions

MedComm
Ischemic stroke remains a leading cause of global disability and death. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have emerged as potent lipid‐lowering agents with expanding therapeutic potential.
Jia Kuang, Lei Hao, Meibiao Zhang, Zhao Yang   +3 more
doaj   +1 more source

The role of proprotein convertase subtilisin/kexin type 9 in atherosclerosis

, 2019
Summary. Dyslipidemia is one of the predominant causes of atherosclerosis and cardiovascular disease (CVD) development. Accordingly, lifestyles approaches and therapeutic targeting of low-density lipoprotein (LDL)-cholesterol remain the main strategies for CVD prevention and treatment.
Vekić, Jelena, Bojanin, Dragana, Spasojević-Kalimanovska, Vesna   +2 more
openaire   +1 more source

Phenotypic homozygous familial hypercholesterolemia successfully treated with proprotein convertase subtilisin/kexin type 9 inhibitors

Clinical Case Reports
Key Clinical Message Recent data reveal phenotypic HoFH patients may be responsive to PCSK9 inhibitors, challenging prior assumptions. Genetic testing advancements now more accurately forecast patient responses to these therapies, improving treatment ...
Ryosuke Tani, Keiji Matsunaga, Yuta Toda, Tomoko Inoue, Hai Ying Fu, Tetsuo Minamino   +5 more
doaj   +1 more source

Anti-PCSK9 antibodies for the treatment of heterozygous familial hypercholesterolemia: patient selection and perspectives

Vascular Health and Risk Management, 2017
Alberico Luigi Catapano,1,2 Angela Pirillo,1,2 Giuseppe Danilo Norata1,3,4 1Department of Pharmacological and Biomolecular Sciences, Università degli Studi di Milano, 2IRCCS Multimedica Hospital, Sesto San Giovanni, 3Center for the Study of ...
Catapano AL, Pirillo A, Norata GD
doaj  

Proprotein Convertase Subtilisin/Kexin Type 9 [PDF]

, 2020
openaire   +1 more source

Therapeutic Strategies for Hypercholesterolemia

healthbook TIMES Das Schweizer Ärztejournal Journal Des Médecins Suisses
A high cholesterol level in the blood is associated with an increased risk of atherosclerosis and its related conditions such as heart attack and stroke.
Georg Noll, André Linka, Thomas Lüscher, Isabella Sudano   +3 more
doaj   +1 more source

Leptin, Resistin, and Proprotein Convertase Subtilisin/Kexin Type 9 [PDF]

The American Journal of Pathology, 2020
Chiara Macchi, Maria Francesca Greco, Margherita Botta, Paola Sperandeo, Paola Dongiovanni, Luca Valenti, Arrigo F.G. Cicero, Claudio Borghi, Maria Giovanna Lupo, Stefano Romeo, Alberto Corsini, Paolo Magni, Nicola Ferri, Massimiliano Ruscica   +13 more
openaire   +1 more source

Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: Efficacy and Safety in the Treatment of Hypercholesterolaemia

European Medical Journal Diabetes, 2018
Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9I) are a new class of medication that has recently arisen to combat hypercholesterolaemia.
Zehra Berberoglu
doaj  

Proprotein Convertase Subtilisin/Kexin Type 9 Measurement [PDF]

, 2020
openaire   +1 more source

Targeting proprotein convertase subtilisin/kexin type 9 in mice and monkeys [PDF]

Current Opinion in Lipidology, 2019
Ya, Wang, Murong, Ma, Jian-An, Wang, Alan, Daugherty, Hong S, Lu   +4 more
openaire   +2 more sources